The clinical use of tofersen in SOD1-mutated ALS already exemplifies this targeted approach, encouraging further development of similar therapies for other mutations such as c9orf72, tardbp, and fus. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.